Pneumatosis Cystoides Coli Related to Acarbose Treatment

Liao, Yen-Hsiu; Liao, Yu-Kai; Lin, Chien‐Hung

doi:10.1038/ajg.2017.88

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No clinical trials and observational studies were found. Details regarding patients’ information and characters are provided in Supplemental Tables S1 and S2 [ 4 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ].…”

Section: Resultsmentioning

confidence: 99%

“…The following supporting information can be downloaded at , Table S1: Clinical features of patients without comorbidities ( n = 10) [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ], and Table S2: Clinical features of patients with comorbidities ( n = 19) [ 4 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ] can be found in the supplementary materials.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus

McKinley

Santiago

Pak

et al. 2022

JCM

View full text Add to dashboard Cite

Alpha-glucosidase inhibitor (αGIs)-induced pneumatosis intestinalis (PI) has been narrated in case reports but never systematically investigated. This study aimed to investigate the concurrency of PI and αGIs. A literature search was performed in PubMed, Google Scholar, WorldCat, and the Directory of Open-Access Journals (DOAJ) by using the keywords “pneumatosis intestinalis”, “alpha-glucosidase inhibitors”, and “diabetes”. In total, 29 cases of αGIs-induced PI in 28 articles were included. There were 11 men, 17 women, and one undefined sex, with a median age of 67. The most used αGI was voglibose (44.8%), followed by acarbose (41.4%) and miglitol (6.8%). Nine (31%) patients reported concomitant use of prednisone/prednisolone with or without immunosuppressants. The main symptoms were abdominal pain (54.5%) and distention (50%). The ascending colon (55.2%) and the ileum (34.5%) were the most affected. Nineteen (65.5%) patients had comorbidities. Patients with comorbidities had higher rates of air in body cavities, the portal vein, extraintestinal tissues, and the wall of the small intestine. Only one patient was found to have non-occlusive mesenteric ischemia. Twenty-five patients were treated with conservative therapy alone, and two patients received surgical intervention. All patients recovered. In conclusion, comorbidities, glucocorticoids, and immunosuppressants aggravate αGIs-induced PI. Conservative therapy is recommended when treating αGIs-induced PI.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus

McKinley

Santiago

Pak

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The principal symptom was abdominal pain associated with the finding of free air under diaphragm. These [12] 65 years, M Secondary Intake of α-glucosidase inhibitors Takahashi et al [13] 17 years, F Idiopathic -Singh et al [14] N/A, F Secondary Systemic sclerosis Asahi et al [15] 67 years, M Secondary Neoplasm Uruga et al [16] 71 years, F Secondary Neoplasm Koysombat et al [17] N/A Secondary Systemic sclerosis Wang et al [18] 56 years, M Idiopathic -48 years, F Secondary Exposing to trichloroethylene 66 years, F Secondary Disease of immune system 72 years, F Secondary Diabetes 64 years, M Secondary Emphysema 24 years, F Secondary Neoplasm Martin-Lagos et al [19] 72 years, M Secondary Chemotherapy Suda et al [20] 80 years, M Idiopathic -Márquez Argente et al [21] 48 years, M Idiopathic de la Serna et al [22] 83 years, M Secondary Chemotherapy Mikami et al [23] 72 years, M Secondary Ulcerative colitis Sugihara et al [24] 48 years, F Secondary Therapy with glucocorticoid Kunishi et al [25] 84 years, M Secondary Intake of α-glucosidase inhibitors Lee et al [26] 68 years, F Secondary Chemotherapy Kang et al [27] 54 years, M Secondary COPD Nakatani et al [28] 70 years, M Secondary Granulomatosis with polyangiitis Rachapalli et al [29] 50 years, M Secondary Neoplasm Jegadeesan et al [30] 51 years, M Secondary Neoplasm Liao et al [31] 84 years, F Idiopathic -Suzuki et al [32] 71 years, F Secondary Connective tissue disease 70 years, F Secondary Connective tissue disease 70 years, M Secondary Connective tissue disease 42 years, F Secondary Connective tissue disease Iida et al [33] 79 years, M Secondary COPD Romano-Munive et al [34] 54 years, F Idiopathic -Venkataramani et al [35] 56 years, F Secondary Neoplasm Faria et al [36] 69 years, M Secondary Neoplasm Fujimi et al [37] 55 years, M Secondary Interstitial pneumonia with corticosteroid therapy Furihata et al [38] 81 years, M Idiopathic -Mima et al [39] 46 years, M Secondary Rheumatoid arthritis Torigoe et al [40] 77 ...…”

Section: Discussionmentioning

confidence: 99%

“Cystamatic” Review: Is Surgery Mandatory for Pneumatosis Cystoides Intestinalis?

Brighi¹,

Vaccari²,

Lauro³

et al. 2019

Dig Dis Sci

View full text Add to dashboard Cite

Introduction Pneumatosis cystoides intestinalis (PCI) is a rare condition characterized by the presence of intramural gas cysts within the small and large intestines. We describe a case of a 70-year-old man admitted to the Emergency Surgery Department for PCI who was treated conservatively. Areas Covered We reviewed 60 cases of PCI described in the international literature over the last 5 years. From our analysis, it appears that the etiology of the gas production within the submucosa or the subserosa of the gastrointestinal tract is still unknown. The rupture of the cysts can lead to pneumoperitoneum that can simulate a surgical emergency. Expert Commentary For patients with PCI, a conservative approach is the treatment of choice, with surgery mandatory only for complicated disease. Keywords Pneumatosis cystoides intestinalis • Conservative management • Spontaneous pneumoperitoneum Abbreviations CTComputed tomography scan PCI Pneumatosis cystoides intestinalis COPD Chronic obstructive pulmonary disease Case Report and EvolutionA 70-year-old man was admitted to the Emergency Department of St. Orsola University Hospital-Bologna-due to the onset of abdominal pain associated with rectorrhagia. His past medical history included hypertension, atrial fibrillation treated with oral anticoagulants, an episode of stroke with dysphagia and dysarthria, cerebrovascular disease, nephrectomy for renal cancer, and diabetes mellitus. In the emergency department, physical examination, blood tests, and chest X-ray were performed. Physical examination was remarkable for upper abdominal direct tenderness in the * A. Lauro

show abstract

“…This disorder has also been associated with the use of α-glucosidase inhibitors, such as acarbose, and patients may present with symptoms of diarrhea, excessive flatulence, mucus discharge, bright red blood per rectum, and constipation. Complications include liver damage, colonic volvulus, pneumoperitoneum, bowel obstruction, and intussusception (1). The underlying mechanism causing these symptoms and bowel-related complications of Pneumatosis Cystoides Intestinalis Secondary to Use of an α-Glucosidase Inhibitor α-glucosidase inhibitors is directly related to the inhibition of glucose uptake by the proximal small bowel.…”

Section: Reviews and Commentary • Images In Radiologymentioning

confidence: 99%

Pneumatosis Cystoides Intestinalis Secondary to Use of an α-Glucosidase Inhibitor

Lin

Wang

2019

Radiology

View full text Add to dashboard Cite

Pneumatosis Cystoides Coli Related to Acarbose Treatment

Cited by 5 publications

References 0 publications

Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus

Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus

“Cystamatic” Review: Is Surgery Mandatory for Pneumatosis Cystoides Intestinalis?

Pneumatosis Cystoides Intestinalis Secondary to Use of an α-Glucosidase Inhibitor

Contact Info

Product

Resources

About